Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia.

Polymorphism in metabolizing enzymes can influence drug response as well as the risk for adverse drug reactions. Nevertheless, there are still few studies analyzing the consequence of polymorphisms for the Glutathione-S-transferases (GST) gene to drug response in chronic myeloid leukemia (CML). This study reports, the influence of GSTP1*B and GSTT1/GSTM1null polymorphisms in response to imatinib in CML patients in a Brazilian population. One hundred thirty-nine CML patients from the Clinical Hospital of Goiânia, Goiás, Brazil, treated with imatinib were enrolled in this study. Genotyping of GSTT1 and GSTM1 genes deletions were performed by qPCR and of GSTP1 gene was performed by RFLP-PCR. The frequency of GSTP1*1B, GSTT1 and GSTM1null polymorphisms were determined for all patients. The influence of each patient's genotypes was analyzed with the patient's response to imatinib treatment. Brazilian CML patients revealed GSTT1 and GSTM1 genes deletions. GSTT1 deletion was found in 19.3% of patients and GSTM1 deletion in 48.7% of patients with CML. GSTT1/GSTM1 deletion was found in 11.7% in Brazilian CML patients. The "G allele" of GSTP1*B, is associated with later cytogenetic response in imatinib therapy. While, the gene presence combined with GG genotype (GSTM1 present/GSTPI-GG) conferred a tend to a later cytogenetic response to patients. GSTP1*B and GSTT1/GSTM1null polymorphisms influence treatment response in CML. Brazilian CML patients presenting GSTP1 AA/AG genotypes alone and in combination with GSTT1 null reach the cytogenetic response faster, while patients presenting GSTP1-GG and GSTMI positive genotypes may take longer to achieve cytogenetic response. As a result, it allows a better prognosis, with the use of an alternative therapy, other than reducing treatment cost.

New germline GATA1 variant in females with anemia and thrombocytopenia.

Familial forms of bone marrow defects are rare disorders and description of new cases are valuable opportunities to clarify the molecular machinery that triggers hematopoiesis and blood formation, as well as risk to malignant transformation. We investigated the genetic scenario and possible patterns of transmission in a rare case of familial myeloid disorder with a history of exposure to pesticides. Blood counts of two proband sisters, age 41 and 42, revealed mild anemia, neutrophilia and thrombocytopenia with bone marrow finding mimicking primary myelofibrosis in the cellular phase. We analyzed the coding regions of 78 myeloid neoplasms-related genes and 16 encoding xenobiotic metabolizing genes using Next-Generation Sequencing. The GATA1 variant c.788C > T, p.T263M, located in the C-terminal zinc finger domain of GATA1, was detected in the DNA of the two sisters. The screening of the other kindreds also revealed the p.T263M variant in the mother and two daughters with the same bone marrow disorder. This is the first report of an alteration in the GATA1 CF domain causing anemia, thrombocytopenia and megakaryocyte proliferation with mild myelofibrosis, correlating a new GATA1 germline variant with myeloid disorder.

Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic

ABSTRACT The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay. This guideline aims to give providers a sense of direction in order to better take care of patients and prioritize care.

Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic.

The novel coronavirus has swept across the world in 2020 and ushered a new era. In the current scenario, it is not clear how patients with myeloproliferative neoplasms (including chronic myelogenous leukemia) should be managed, considering the risk of therapy, the need for social distancing and the risk of untimely therapy discontinuation of delay. This guideline aims to give providers a sense of direction in order to better take care of patients and prioritize care.

Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges.

Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical course. As a rare disease, with no randomized prospective trials, there is no standard of care for SMZL so far. Splenectomy has been done for many years as an attempt to control disease, but nowadays it has not been encouraged as first line because of new advances in therapy as rituximab, that are as effective with minimal toxicity. Facing these controversies, this review highlights advances in the literature regarding diagnosis, prognostic factors, treatment indications and therapeutic options.

Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges

ABSTRACT Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkin's lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical course. As a rare disease, with no randomized prospective trials, there is no standard of care for SMZL so far. Splenectomy has been done for many years as an attempt to control disease, but nowadays it has not been encouraged as first line because of new advances in therapy as rituximab, that are as effective with minimal toxicity. Facing these controversies, this review highlights advances in the literature regarding diagnosis, prognostic factors, treatment indications and therapeutic options.

Ocorrência de múltiplas neoplasias em paciente portador de leucemia mieloide crônica: relato de caso / Occurence of multiple neoplasms in patient with chronic myeloid leukemia: case report

Introdução: A leucemia mieloide crônica é um distúrbio mieloproliferativo clonal com uma anormalidade citogenética específica, resultante da translocação entre os cromossomos 9 e 22 com consequente produção de uma proteína com atividade tirosina quinase alterada. Tratamentos históricos com drogas como bussulfan, hidroxiureia e interferon passaram a ser pouco utilizados devido ao surgimento dos inibidores de tirosina quinase, cujo principal representante é o mesilato de imatinibe. Esse fármaco é a terapia de primeira linha, sendo bem tolerado pelos pacientes e com baixo risco de eventos adversos severos. Entretanto, com cerca de dez anos de uso, ainda há preocupação com efeitos colaterais em longo prazo, tais como o desenvolvimento de segunda neoplasia. Objetivo: Descrever a ocorrência de múltiplas neoplasias em um portador de leucemia mieloide crônica. Método: Relata-se o caso de um paciente com leucemia mieloide crônica há 13 anos, tendo utilizado hidroxiureia e interferon como terapias prévias e em uso de mesilato de imatinibe há nove anos. Resultados: Há dois anos, o paciente apresentou dois nódulos em coxa esquerda que foram totalmente ressecados. Diagnosticou-se lipossarcoma mixoide e o paciente foi submetido à radioterapia. A tomografia computadorizada do abdomên de controle aos seis meses detectou nódulo espiculado na gordura mesenquimal adjacente ao jejuno/íleo. Feita laparotomia exploradora e ressecção, o anatomopatológico demonstrou fibromatose desmoide. Conclusão: O portador de tumor maligno tem risco aumentado de desenvolver uma segunda neoplasia, que pode dessa forma ocorrer nos portadores de leucemia mieloide crônica. Essa associação pode estar relacionada aos fármacos usados no tratamento da mesma.

[Retinal manifestations in patients with sickle cell disease referred to a University Eye Hospital]. / Alterações retinianas apresentadas em pacientes portadores de hemoglobinopatia falciforme atendidos em um Serviço Universitário de Oftalmologia.

PURPOSE: To identify retinal manifestations in patients with sickle cell disease referred to a reference eye hospital in Goiânia (GO). METHODS: Ophthalmic evaluation was made in 50 patients (100 eyes) with sickle cell disease to evaluate the most common manifestations of this group. RESULTS: Hemoglobinopathy SS was the most commonly found, followed by hemoglobin SC, AS and Stahl. Twenty-two percent of the patients had retinal changes, of these 73% were male. Retinal changes observed were: "sea fan", "black sunburst", vitreous hemorrhage, and retinal detachment. In the classification of retinopathy, 73% had proliferative form, seen in the types AS and SC and 27% had non-proliferative retinopathy, seen in patients with SS type. CONCLUSIONS: We observed a large numbers of patients with retinal changes, most of them with hemoglobinopathy SC, followed by AS and SS groups. The proliferative changes were the most commonly observed. Vitreous hemorrhage and retinal detachment were the most prevalent manifestations in proliferative retinopathy and showed to be more common in patients with SC hemoglobinopathy in the studied population.

Alterações retinianas apresentadas em pacientes portadores de hemoglobinopatia falciforme atendidos em um Serviço Universitário de Oftalmologia / Retinal manifestations in patients with sickle cell disease referred to a University Eye Hospital

OBJETIVOS: Identificar os principais achados fundoscópicos em pacientes portadores de anemia falciforme encaminhados a um Serviço Oftalmológico de Referência em Goiânia (GO). MÉTODOS: Foram realizados exames oftalmológicos em 50 pacientes (100 olhos) portadores de hemoglobinopatia falciforme para observar quais as alterações retinianas mais comuns nesse grupo. RESULTADOS: O tipo de hemoglobinopatia mais encontrado foi o SS, seguido pelas hemoglobinopatias SC, AS e Sthal. Dentro da amostra estudada, 22 por cento apresentaram alterações retinianas. Destes 73 por cento eram do sexo masculino. A alteração retinianas encontradas foram: "sea fan", "black sunburst", hemorragia vítrea e descolamento de retina. Em relação à classificação da retinopatia, 73 por cento apresentaram a forma proliferativa, sendo vista nos tipos AS e SC e 27 por cento apresentaram a forma não-proliferativa da retinopatia, sendo vista nos portadores do tipo SS. CONCLUSÃO: Foi observado elevado número de pacientes com alterações retinianas na amostra estudada, sendo o maior número em portadores da hemoglobinopatia SC, seguido dos grupos AS e SS. As alterações proliferativas foram as mais observadas. Hemorragia vítrea e descolamento de retina foram as manifestações proliferativas de maior prevalência e mostraram ser mais frequente em portadores da hemoglobinopatia SC na população estudada.

PURPOSE: To identify retinal manifestations in patients with sickle cell disease referred to a reference eye hospital in Goiânia (GO). METHODS: Ophthalmic evaluation was made in 50 patients (100 eyes) with sickle cell disease to evaluate the most common manifestations of this group. RESULTS: Hemoglobinopathy SS was the most commonly found, followed by hemoglobin SC, AS and Stahl. Twenty-two percent of the patients had retinal changes, of these 73 percent were male. Retinal changes observed were: "sea fan", "black sunburst", vitreous hemorrhage, and retinal detachment. In the classification of retinopathy, 73 percent had proliferative form, seen in the types AS and SC and 27 percent had non-proliferative retinopathy, seen in patients with SS type. CONCLUSIONS: We observed a large numbers of patients with retinal changes, most of them with hemoglobinopathy SC, followed by AS and SS groups. The proliferative changes were the most commonly observed. Vitreous hemorrhage and retinal detachment were the most prevalent manifestations in proliferative retinopathy and showed to be more common in patients with SC hemoglobinopathy in the studied population.

Evaluation of quality of life of patients with sickle cell disease in a General Hospital of Goiás, Brazil

INTRODUÇÃO: A doença falciforme é a doença hereditária mais frequente no nosso país. O portador apresenta acometimentos físico, emocional e social, e sua qualidade de vida pode estar comprometida. OBJETIVO: Avaliar a qualidade de vida dos doentes falciformes em tratamento no Hospital das Clínicas da Universidade de Goiás. MÉTODO: Foram entrevistados 60 sujeitos entre 14 e 60 anos, doentes falciformes, em tratamento no Hospital das Clínicas. Aplicou-se o WHOQOL-Bref (instrumento avaliativo de qualidade de vida da Organização Mundial de Saúde - OMS), o questionário étnico-racial e o sociodemográfico. A significância foi definida por um erro padrão de 5 por cento (p < 0,05). Os sujeitos eram do sexo feminino em 53,3 por cento e solteiros em 71,7 por cento. A média da idade foi de 27 anos e o nível educacional até o primeiro grau completo foi de 51,7 por cento. RESULTADOS: A maioria considerou-se parda (46,7 por cento) e a minoria, negra (11,7 por cento). Apenas 6,7 por cento disseram ser vítimas de preconceito devido à cor e 33,3 por cento disseram ser vítimas de preconceito devido à doença. Os sujeitos relataram ligação entre doença e sua cor em 48,3 por cento. A qualidade de vida foi avaliada negativa em 6,7 por cento e, em 70 por cento, positiva. Apresentaram satisfação negativa quanto à saúde 23,3 por cento dos sujeitos e, em 48,3 por cento, a satisfação foi positiva. Os escores do WHOQOL-Bref, de 0 a 100 foram: domínio físico (57,32), psicológico (66,03), social (69,86) e ambiental (52,76). CONCLUSÃO: Houve correlação significativa entre preconceito devido à doença e nível educacional, e entre idade e todos os domínios. A doença falciforme limita a vida do portador, com comprometimento da qualidade de vida. A doença está perdendo o caráter de "black related disease", coincidindo com a miscigenação racial brasileira.

INTRODUCTION: Sickle cell disease is the most common inherited disease in Brazil. Patients are known to suffer physical, emotional and social impairment and their quality of life may well be involved. METHOD: The quality of life of sickle cell disease patients treated in Hospital das Clínicas of the Universidade Federal de Goiás was evaluated. Sixty patients with ages ranging from 14 to 60 years old were interviewed. The WHOQOL-Bref (a quality of life validation instrument of the World Health Organization), and the ethnical-racial, and sociodemographic questionnaires were administered. A standard error of 5 percent (p-value < 0.05) was considered acceptable. RESULTS: The mean age of the participants was 27 years old, 53.3 percent of the patients were women, 71.7 percent were single and 51.7 percent had completed elementary school. The majority classified themselves as mulattos (46.7 percent) and the minority Blacks (11.7 percent). Only 6.7 percent considered themselves victims of racial discrimination because of their skin color but 33.3 percent considered themselves victims of discrimination due to sickle cell disease. The patients 48.3 percent reported an association between their disease and their skin color. The quality of life was considered bad by 6.7 percent and good by 70 percent. A total of 48.3 percent considered their lives to be satisfactory and 23.3 percent to be unsatisfactory. The scores obtained from the WHOQOL-Bref (from 0 to 100) were: 57.32 for physical, 66.03 for psychological, 69.86 for social and 52.76 for environmental domains. There were significant correlations of discrimination due to the disease with educational level and age with all the WHOQOL-Bref domains. CONCLUSION: Sickle cell disease significantly limits the quality of life of patients. Also, sickle cell disease, coinciding with the racial miscegenation, is losing its "black-related disease" character in Brazil.

Pesar antes e apos a mamada e uma boa medida do volume do leite ingerido? / To weight before and after the sucking is one good means of the volume of milk ingested

Foi estudada a eficacia de dois diferentes tipos de balancas, uma tradicional e outra eletronica, na medida do peso da crianca antes e depois mamada, como forma de se inferir o volume de leite ingerido. Foram avaliadas nos Bercarios do HCFMRP-USP 329 diferentes criancas de ambos os sexos, com peso de nascimento entre 1150g e 4490g de idade pos-natal variando de 1 a 30 dias. As criancas receberam quantidades variadas de leite (de 0,8 a 86g), por mamadeira. O leite oferecido foi quantificado por meio da diferenca de peso da mamadeira antes e apos a mamada aferidos em balanca de precisao. Antes da mamada a crianca era pesada com roupa em uma das duas balancas analisadas. Apos a mamada, semque houvesse mudanca de roupas e fraldas, a crianca era novamente pesada pelo mesmo pesquisador. Na balanca tradicional, se tomadas todas as medidas em conjunto, encontra-se boa correlacao entre o peso do leite oferecido e o ganho de peso detectado (r=0,72;p<0,001), porem verifica-se grande variabilidade de peso das criancas, especialmente na faixa de ingesta menor de 30g. Com a balanca eletronica, a variabilidade encontrada foi bem menor do que com a balanca tradicional, porem ainda dentro de limites nao satisfatorios. A correlacao entre ganho de peso ede leite ingerido foi de 0.89,p<0,01. Ate que balancas mais sensiveis estejam disponiveis, a pratica de pesar a crianca antes e apos as mamadas, como metodo de avaliacao da quantidade de leite ingerida nao deve ser recomendada .